BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program
BioVaxys Technology Corp. announced progress in developing a pan-sarbecovirus vaccine in collaboration with The Ohio State University. The study focuses on BVX-1021, a booster vaccine aimed at inducing immune responses to various sarbecoviruses, including SARS-CoV-2 variants. They are preparing new recombinant SARS-1 protein to enhance study reproducibility. Results from neutralizing antibody studies are expected by late August 2022. This initiative aligns with WHO's call for enhanced vaccines against evolving strains, reflecting a critical need for effective pan-sarbecovirus solutions.
- Collaboration with Ohio State University for the pan-sarbecovirus vaccine development.
- Preparation of surrogate virus neutralization assays for various SARS-CoV-2 variants.
- Anticipation of neutralizing antibody study results by late August 2022.
- Alignment with WHO's critical need for pan-sarbecovirus vaccines.
- Delays in study results due to the re-synthesis of recombinant SARS-1 protein.
- Covid-19 lockdowns in Shanghai have impacted the production timeline.
Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need
VANCOUVER, BC, June 3, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that The Ohio State University ("Ohio State"), its research collaborator that is jointly evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine"), has completed preparation of the surrogate virus neutralization assays for the SARS-CoV-2 variants, as well as Pangolin-Cov-GD1 and Bat-CoV-RaTG13 sarbecoviruses. The next step will be immunizing the test animals with BVX-1021, BioVaxys' "booster" vaccine to be administered with current SARS-CoV-2 vaccines, to target sarbecoviruses.
BVX-1021 is the subject of an ongoing research collaboration between Ohio State and BioVaxys that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses. These are a family of viruses that include SARS-CoV-2 and current 'Variants of Concern' such as Delta and Omicron (as well as at least ten additional variants that are currently being globally monitored), SARS-CoV-1, and a broad range of other potentially dangerous zoonotic viruses. The collaboration, which began earlier this year, is evaluating the combination of BioVaxys' BVX-0320 and BVX-1021 in a guinea pig model. The major endpoints of the study are the development of virus-neutralizing antibodies to live virus SARS-CoV-2 and other sarbecoviruses, including bat and pangolin SARS-related coronaviruses. Bats are a major reservoir of many strains of SARS, with several strains have been identified in palm civets, which were likely ancestors of SARS-CoV-1 ("SARS-1") (Journal of Virology. 84 (6): 2808–19, 2010). The presence of neutralizing antibodies in the animal model would strongly suggest that BVX-1021 would confer an additional immune response across all sarbecoviruses in those people fully vaccinated for Covid-19 as well as those with natural immunity.
Recent yields of recombinant SARS-1 protein obtained from an external supplier for the bioproduction of BVX-1021 were determined to contain the presence of a natural protein aggregate byproduct in addition to the SARS-1 protein. Kenneth Kovan, BioVaxys President and Chief Operating Officer stated, "Although this likely would not have impacted the neutralizing antibody assays of the study, our team felt it prudent for scientific reproducibility to re-synthesize a new yield of recombinant SARS-1 protein specifically screening out the extraneous protein aggregate, even though it would incur some delay in obtaining study results; the Covid-19 lockdown situation in Shanghai further impacted the lead time for production of the SARS-1 protein by our Shanghai-based supplier. MilliporeSigma, our contract manufacturer, is now able to begin the bioproduction of new yields of BVX-1021 vaccine for the study. We now anticipate data from the neutralizing antibody study by late August 2022."
BioVaxys and Ohio State were recently invited by The Coalition for Epidemic Preparedness Innovations ("CEPI") to present their strategy for a pan-sarbecovirus vaccine to a panel of CEPI vaccine experts. Following this presentation, the Company and Ohio State were invited to return and deliver an update following completion of the animal studies. Based in Oslo, London, and Washington, DC, CEPI is a global foundation that directs public, private, and philanthropic funding towards vaccines targeting major unmet needs (https://cepi.net/).
In January 2022, the World Health Organization ("WHO") Covid Vaccines Research Expert Group presented a report on the critical need for a pan-sarbecovirus vaccine ("Why do we need a pan-sarbecovirus?" January 28, 2022, World Health Organization). This report stated that there is a "very high urgency for pan-sarbecovirus vaccines: Current vaccines are becoming less effective against evolving variants, and waning even of booster vaccine response indicates that we don't have a practical vaccine for the future. Although severe disease is critical, a pan-sarbecovirus vaccine may have a better chance of blocking transmission and facilitating herd immunity, and are expected to be more durable."
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Government & Media Relations
JB&A, Inc.
Davin Shinedling
davin@jennibyrne.com
+1 (647) 991-6447
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biovaxys-and-the-ohio-state-university-progress-pan-sarbecovirus-vaccine-research-program-301560830.html
SOURCE BioVaxys Technology Corp.
FAQ
What is the latest update on BioVaxys' BVX-1021 vaccine?
How does the WHO view the need for a pan-sarbecovirus vaccine?
What challenges are BioVaxys facing in their vaccine development?
What are the primary endpoints of the BioVaxys vaccine study?
What is the significance of the collaboration between BioVaxys and Ohio State?
